4-[(2-Chloro-9H-purin-6-ylamino)-methyl]-benzoic acid methyl ester | 199987-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 4-[(2-Chloro-9H-purin-6-ylamino)-methyl]-benzoic acid methyl ester
• 英文别名: methyl 4-[[(2-chloro-7H-purin-6-yl)amino]methyl]benzoate
• CAS: 199987-87-6
• 化学式: C₁₄H₁₂ClN₅O₂
• 分子量: 317.735
• InChiKey: OVPGMHDEQLGZFY-UHFFFAOYSA-N

物化性质

• 沸点：
  479.4±55.0 °C(Predicted)
• 密度：
  1.52±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  92.8
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-[(2-Chloro-9H-purin-6-ylamino)-methyl]-benzoic acid methyl ester 在 水 、 potassium carbonate 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 4-[[(2-chloro-9-cyclopentyl-9H-purin-6-yl)amino]methyl]benzoic acid
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer

  摘要：

  In the current study, we have designed and synthesized a series of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent kinase2 (CDK2) dual inhibitors by integrating purine-based pharmacophore into the recognition cap group of CS055. The representative compound 14d with excellent anti-proliferative activities towards five solid cancer cells, showed potent inhibitory activities against HDAC1, HDAC2 and CDK2 with IC50 values of 70.7 nM, 23.1 nM and 0.80 mu M, respectively. Besides, compound 14d could effectively block the cell cycle in the G2/M phase and induce apoptosis, which might be related to increasing intracellular ROS levels. Importantly, compound 14d exhibited desirable pharmacokinetic (PK) properties with the intraperitoneal bioavailability of 50.8% in ICR mice, and potent in vivo antitumor activity in the HCT116 xenograft model. Therefore, compound 14d could be considered as a promising lead compound for the development of multitargeting anticancer agents. (C) 2020 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2020.112322
• 作为产物：
  描述：

  4-氨甲基苯甲酸甲酯盐酸盐 、 2,6-二氯嘌呤 在 碳酸氢钠 作用下， 以 水 为溶剂， 生成 4-[(2-Chloro-9H-purin-6-ylamino)-methyl]-benzoic acid methyl ester
  参考文献：
  名称：

  Inhibitors of histone deacetylase

  摘要：

  本发明涉及组蛋白去乙酰化酶的抑制。本发明提供了用于抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和状况的药物组合物和方法。

  公开号：

  US06897220B2

文献信息

• Inhibitors of histone deacetylase
  申请人：Delorme Daniel

  公开号：US06897220B2

  公开（公告）日：2005-05-24

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  本发明涉及组蛋白去乙酰化酶的抑制。本发明提供了用于抑制组蛋白去乙酰化酶酶活性的化合物和方法。本发明还提供了用于治疗细胞增殖性疾病和状况的药物组合物和方法。
• [EN] INHIBITORS OF HISTONE DEACETYLASE<br/>[FR] INHIBITEURS DE L'HISTONE DEACETYLASE
  申请人：METHYLGENE INC

  公开号：WO2004069823A1

  公开（公告）日：2004-08-19

  The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

  该发明涉及抑制组蛋白去乙酰化酶的技术。该发明提供了抑制组蛋白去乙酰化酶酶活性的化合物和方法。该发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。
• INHIBITORS OF HISTONE DEACETYLASE
  申请人：Methylgene, Inc.

  公开号：EP1429765A2

  公开（公告）日：2004-06-23
• US6897220B2
  申请人：——

  公开号：US6897220B2

  公开（公告）日：2005-05-24
• US7595343B2
  申请人：——

  公开号：US7595343B2

  公开（公告）日：2009-09-29